Abstract
Olanzapine is widely used during pregnancy to manage mood and psychotic disorders with overall beneficial effects. There have been past reports of olanzapine exposure during early pregnancy and clubfoot in two newborns from India and Israel. We report a woman in Nepal diagnosed with schizophrenia and treated with olanzapine throughout the pregnancy delivering a baby boy with congenital talipes equinovarus deformity. Like in many other low-income settings, pregnancy was unplanned, and pre-conception counselling was not done. Research in mice has revealed the negative effects of olanzapine on bone development. Further reports would strengthen this potential association between exposure to olanzapine in the first trimester and the occurrence of clubfoot in the baby.
This is a preview of subscription content, log in via an institution to check access.
References
Agarwal, Dahuja M, & Tyagi M (2018) Risks associated with psychotropic drugs during pregnancy. Ann Indian Psychiatry 2(1):58. https://doi.org/10.4103/AIP.AIP_30_17
Anderson KN, Ailes EC, Lind JN, Broussard CS, Bitsko RH, Friedman JM, Bobo WV, Reefhuis J, Tinker SC (2020) Atypical antipsychotic use during pregnancy and birth defect risk: national birth defects prevention study, 1997–2011. Schizophr Res 215:81–88. https://doi.org/10.1016/J.SCHRES.2019.11.019
Andrade C (2021) Major congenital malformations associated with exposure to second-generation antipsychotic drugs during pregnancy. J Clin Psychiatry 82(5), 0–0. https://doi.org/10.4088/JCP.21F14252
Bearak J, Popinchalk A, Ganatra B, Moller A-B, Tunçalp Ö, Beavin C, Kwok L, Alkema L (2020) Unintended pregnancy and abortion by income, region, and the legal status of abortion estimates from a comprehensive model for 1990–2019. Lancet Glob Health 8(9):e1152–e1161. https://doi.org/10.1016/S2214-109X(20)30315-6
Brunner E, Falk DM, Jones M, Dey DK, Shatapathy CC (2013) Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol 14(1):1–8. https://doi.org/10.1186/2050-6511-14-38
Caiaffo V, de Melo, R, Santos C and Duarte B (2012) Effect of different doses of olanzapine on mice’s bone tissue. https://www.researchgate.net/profile/Vitor-Caiaffo/publication/280236441_EFFECT_OF_DIFFERENT_DOSES_OF_OLANZAPINE_ON_MICE%27S_BONE_TISSUE/links/55ae822f08aee0799220e12e/EFFECT-OF-DIFFERENT-DOSES-OF-OLANZAPINE-ON-MICES-BONE-TISSUE.pdf
Chen C, Kaushal N, Scher DM, Doyle SM, Blanco JS, Dodwell ER (2018) Clubfoot etiology: a meta-analysis and systematic review of observational and randomized trials. J Pediatr Orthop 38(8):e462–e469. https://doi.org/10.1097/BPO.0000000000001191
Diméglio A, Souchet P, Mazeau P, Mazeau P, Bonnet F (1995) Classification of clubfoot. J Pediatr Orthop B 4(2):129–136. https://doi.org/10.1097/01202412-199504020-00002
Edinoff AN, Sathivadivel N, McNeil SE, Ly AI, Kweon J, Kelkar N, Cornett EM, Kaye AM, Kaye AD (2022) Antipsychotic use in pregnancy: patient mental health challenges, teratogenicity, pregnancy complications, and postnatal risks. Neurol Int 14(1):62–74. https://doi.org/10.3390/NEUROLINT14010005
Ellfolk M, Leinonen MK, Gissler M, Kiuru-Kuhlefelt S, Saastamoinen L, Malm H (2021) Second-generation antipsychotic use during pregnancy and risk of congenital malformations. Eur J Clin Pharmacol 77(11):1737–1745. https://doi.org/10.1007/S00228-021-03169-Y
FDA (n.d.) ZYPREXA (olanzapine) label. Retrieved October 21, 2021, from www.fda.gov/medwatch
Ifteni P, Moga MAM, Burtea V and Correll CU (2014) Schizophrenia relapse after stopping olanzapine treatment during pregnancy: a case report. Ther Clin Risk Manag 901. https://doi.org/10.2147/tcrm.s70545
Kalfoglou AL (2016) Ethical and clinical dilemmas in using psychotropic medications during pregnancy. AMA J Ethics 18(6):614–623. https://doi.org/10.1001/JOURNALOFETHICS.2016.18.6.STAS1-1606
Li X, Nagy TR (2013) Atypical antipsychotic drugs inhibit trabecular bone accrual in C57BL/6J mice. Int J Body Compos Res 11(1):21 (/pmc/articles/PMC4023556/)
McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, Green L, Gregoire A, Howard LM, Jones I, Khalifeh H, Lingford-Hughes A, McDonald E, Micali N, Pariante CM, Peters L, Roberts A, Smith NC, Taylor D, … Psychopharmacology, endorsed by the B. A. for (2017) British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 31(5): 519–552. https://doi.org/10.1177/0269881117699361
Newport DJ, Calamaras MR, DeVane CL, Donovan J, Beach AJ, Winn S, Knight BT, Gibson BB, Viguera AC, Owens MJ (2007) Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 164(8):1214–1220
Park Y, Hernandez-Diaz S, Bateman BT, Cohen JM, Desai RJ, Patorno E, Glynn RJ, Cohen LS, Mogun H, Huybrechts KF (2018) Continuation of atypical antipsychotic medication during early pregnancy and the risk of gestational diabetes. Am J Psychiatry 175(6):564. https://doi.org/10.1176/APPI.AJP.2018.17040393
Pavone V, Chisari E, Vescio A, Lucenti L, Sessa G, Testa G (2018) The aetiology of idiopathic congenital talipes equinovarus: a systematic review. J Orthop Surg Res 13(1):1–11
Pernia S, DeMaagd G (2016) The new pregnancy and lactation labelling rule. Pharm Ther 41(11):713 (/pmc/articles/PMC5083079/)
Smythe T, Kuper H, Macleod D, Foster A, Lavy C (2017) Birth prevalence of congenital talipes equinovarus in low- and middle-income countries: a systematic review and meta-analysis. Tropical Med Int Health 22(3):269–285. https://doi.org/10.1111/TMI.12833
Thanigaivel R, Bretag-Norris R, Amos A and McDermott B (2021) A systematic review of maternal and infant outcomes after clozapine continuation in pregnancy. https://doi.org/10.1080/13651501.2021.1936070
Thomas K and Saadabadi A (2021) Olanzapine. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK532903/
Ullah MS, Ferdous KMN, Shahjahan M, Sayed SA (2013) Management of congenital talipes equino varus (CTEV) by Ponseti casting technique in neonates: our experience. Journal of Neonatal Surgery 2(2):17 (/pmc/articles/PMC4420377/)
Viguera AC, Freeman MP, Góez-Mogollón L, Sosinsky AZ, McElheny SA, Church TR, Young Av, Caplin PS, Chitayat D, Hernández-Díaz S and Cohen LS (2021) Reproductive safety of second-generation antipsychotics: updated data from the Massachusetts General Hospital National Pregnancy Registry for atypical antipsychotics. J Clin Psychiatry 82(4), 0–0. https://doi.org/10.4088/JCP.20M13745
Wlodarczyk BJ, Ogle K, Lin LY, Bialer M, Finnell RH (2015) Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord 17(6):615–625. https://doi.org/10.1111/BDI.12325
Yeshayahu Y (2007) The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities. Am J Psychiatry 164(11):1759–1760. https://doi.org/10.1176/APPI.AJP.2007.07010176
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
The research was conducted in accordance with the principles embodied in the Declaration of Helsinki and in accordance with local statutory requirements. The participants gave written informed consent to participate in the study, and we confirm that consent was given for publication by all participants. Ethical clearance from the Institutional Review Board was not required for the said case report.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Gyawali, R., Baral, A., Upreti, D. et al. Novel report on congenital talipes equinovarus (CTEV) following olanzapine exposure during pregnancy: case report and short review. Arch Womens Ment Health 25, 671–674 (2022). https://doi.org/10.1007/s00737-022-01221-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00737-022-01221-z